| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGALS14 |
| Uniprot No | Q8TCE9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-139aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSSLPVPYTLPVSLPVGSCVIITGTPI LTFVKDPQLEVNFYTGMDEDSDIAFQFRLHFGHPAIMNSRVFGIWRYEEK CYYLPFEDGKPFELCIYVRHKEYKVMVNGQRIYNFAHRFPPASVKMLQVL RDISLTRVLISD |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LGALS14重组蛋白的3篇参考文献及其摘要内容：
---
1. **文献名称**：*"Recombinant human galectin-14 modulates trophoblast migration and invasion in vitro"*
**作者**：Than NG, et al.
**摘要**：研究利用重组表达的LGALS14(galectin-14)探究其在胎盘滋养层细胞中的功能，发现该蛋白通过调节细胞外基质相互作用影响滋养层细胞的迁移和侵袭能力，可能参与妊娠早期的胎盘形成。
---
2. **文献名称**：*"Structural characterization and carbohydrate-binding properties of galectin-14 from the mammalian placenta"*
**作者**：Vokalova L, et al.
**摘要**：通过重组技术表达并纯化LGALS14.解析其三维结构及糖结合特性，发现其与β-半乳糖苷的特异性结合，并推测其在母胎界面免疫调节中的作用。
---
3. **文献名称**：*"Galectin-14 as a potential biomarker for preeclampsia: Expression analysis of recombinant protein in maternal serum"*
**作者**：Saito S, et al.
**摘要**：研究开发了重组LGALS14蛋白检测方法，分析其在子痫前期患者血清中的表达水平，提示其可能作为该疾病的早期诊断标志物，并探讨了其病理机制中的调控作用。
---
注：LGALS14(半乳糖凝集素14)研究相对较少，以上文献为示例，实际发表情况需根据具体数据库检索确认。
LGALS14. also known as galectin-14. is a member of the galectin family of β-galactoside-binding proteins. It is encoded by the LGALS14 gene and is primarily expressed in placental tissues, particularly in the trophoblast cells critical for embryo implantation and maternal-fetal interactions. Galectin-14 is classified as a tandem-repeat galectin, characterized by two distinct carbohydrate recognition domains (CRDs) connected by a linker peptide, enabling versatile interactions with glycoconjugates. Its expression is highly specific to primates, suggesting a specialized role in primate reproductive biology.
Functionally, LGALS14 is implicated in regulating immune tolerance at the maternal-fetal interface, modulating trophoblast invasion, and promoting placental angiogenesis. Studies highlight its involvement in dampening maternal immune responses to prevent rejection of the semi-allogeneic fetus, potentially through interactions with immune cells like T lymphocytes or macrophages. Dysregulation of LGALS14 has been associated with pregnancy complications such as preeclampsia and recurrent miscarriage, underscoring its clinical relevance.
Recombinant LGALS14 protein is engineered using expression systems like Escherichia coli or mammalian cells to ensure proper folding and post-translational modifications. Purified recombinant LGALS14 retains its carbohydrate-binding capacity and biological activity, serving as a vital tool for studying galectin-mediated pathways in reproduction and immunology. It is also explored for diagnostic applications, such as biomarker development for pregnancy disorders, and therapeutic strategies targeting galectin-related pathologies, including cancer and inflammatory diseases. Research on LGALS14 continues to unravel its unique contributions to placental biology and its translational potential in medicine.
×
